Opportunity stated: "Hilarious. Aileron started out the same way Biocurex and every other biotech company starts."
You obviously have a lapse of memory in how BioCurex started and I doubt few if any companies have started that way and been successful.
Let me give you a review. BioCurex does a reverse merger where a group of 80 some unknown investors are allowed to retain 90% of the 10 million outstanding shares at the git go. The company starts with no money at all and begins to attempt selling stock to investors. The management running the company pumped the stock to over $5 and by 2003, they are all gone with their shares sold and the stock back at less than 5 cents.
Aileron Therapeutics is a private company that was obviously well funded. That is how most successful biotech companies begin, not with reverse merger and highly questionable transactions involved.
I don't know if Moro will ever be successful but the odds are stacked way against him. He has now tapped the secondary stock offering market with massive dilution and the stock has gone nowhere. I doubt that route will be available again. Taglich states that the company has funds until mid next year. What does Moro do then?
News 
Market Data 
Discover 
